Atrial Fibrillation

This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower  ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion

News

May 17, 2018 — Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 ...

Home May 17, 2018
Home
Technology | Patient Monitors

May 16, 2018 — Itamar Medical Ltd. announced the launch of SleePath, the first integrated e-health sleep apnea care ...

Home May 16, 2018
Home
News | Atrial Fibrillation

May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and new ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricular ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception and ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 11, 2018 — A new study finds that integrating two separate clinical risk score models more accurately helps ...

Home May 11, 2018
Home
News | ECG Monitoring Services

May 9, 2018 – Medicalgorithmics S.A. will present the results of a large study evaluating online versus offline electroc ...

Home May 09, 2018
Home
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Feature | Antiplatelet and Anticoagulation Therapies

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first ...

Home May 07, 2018
Home
Technology | EP Mapping and Imaging Systems

May 3, 2018 — The U.S. Food and Drug Administration (FDA) has granted market clearance for the Abbott Advisor HD Grid ...

Home May 03, 2018
Home
News

April 12, 2018 — Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic ...

Home April 12, 2018
Home
News | Atrial Fibrillation

March 27, 2018 — Depression may increase the risk for atrial fibrillation, the most common heart rhythm disorder that ...

Home March 27, 2018
Home
News | Wearables

March 19, 2018 — For people at heightened risk for atrial fibrillation (AFib), a common heart rhythm disorder that also ...

Home March 19, 2018
Home
News | ACC

March 15, 2018 – A newly-designed wristband and corresponding app that works with a smartwatch can accurately display ...

Home March 15, 2018
Home
ACC 2018 highlights and trends.  #acc.18, #ACC, #ACC2018
Feature | ACC

The rapid pace of change continues to be a hallmark in cardiovascular medicine and many see that pace accelerating. In ...

Home January 31, 2018
Home
Subscribe Now